文献
J-GLOBAL ID:202102263915087538
整理番号:21A0181402
臨床開発における強力で選択的なポリ(ADP-リボース)ポリメラーゼ(PARP)阻害剤パミパリブ(BGB-290)の発見【JST・京大機械翻訳】
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
著者 (34件):
Wang Hexiang
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Ren Bo
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Liu Ye
(Department of Biochemistry, BeiGene (Beijing) Co., Ltd.)
,
Jiang Beibei
(Department of in Vivo Pharmacology, BeiGene (Beijing) Co., Ltd.)
,
Guo Yin
(Department of Discovery Biology, BeiGene (Beijing) Co., Ltd.)
,
Wei Min
(Department of Biochemistry, BeiGene (Beijing) Co., Ltd.)
,
Luo Lusong
(Department of Discovery Biology, BeiGene (Beijing) Co., Ltd.)
,
Kuang Xianzhao
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Qiu Ming
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Lv Lei
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Xu Hong
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Qi Ruipeng
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Yan Huibin
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Xu Dexu
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Wang Zhiwei
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Huo Chang-Xin
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
,
Zhu Yutong
(Department of Discovery Biology, BeiGene (Beijing) Co., Ltd.)
,
Zhao Yuan
(Department of Discovery Biology, BeiGene (Beijing) Co., Ltd.)
,
Wu Yiyuan
(Department of Discovery Biology, BeiGene (Beijing) Co., Ltd.)
,
Qin Zhen
(Department of Discovery Biology, BeiGene (Beijing) Co., Ltd.)
,
Su Dan
(Department of DMPK, BeiGene (Beijing) Co., Ltd.)
,
Tang Tristin
(Department of in Vivo Pharmacology, BeiGene (Beijing) Co., Ltd.)
,
Wang Fan
(Department of DMPK, BeiGene (Beijing) Co., Ltd.)
,
Sun Xuebing
(Department of Biochemistry, BeiGene (Beijing) Co., Ltd.)
,
Feng Yingcai
(Department of Biochemistry, BeiGene (Beijing) Co., Ltd.)
,
Peng Hao
(Department of Biochemistry, BeiGene (Beijing) Co., Ltd.)
,
Wang Xing
(Department of in Vivo Pharmacology, BeiGene (Beijing) Co., Ltd.)
,
Gao Yajuan
(Department of in Vivo Pharmacology, BeiGene (Beijing) Co., Ltd.)
,
Liu Yong
(Department of in Vivo Pharmacology, BeiGene (Beijing) Co., Ltd.)
,
Gong Wenfeng
(Department of in Vivo Pharmacology, BeiGene (Beijing) Co., Ltd.)
,
Yu Fenglong
(Department of in Vivo Pharmacology, BeiGene (Beijing) Co., Ltd.)
,
Liu Xuesong
(Department of Biochemistry, BeiGene (Beijing) Co., Ltd.)
,
Wang Lai
(Department of in Vivo Pharmacology, BeiGene (Beijing) Co., Ltd.)
,
Zhou Changyou
(Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd.)
資料名:
Journal of Medicinal Chemistry
(Journal of Medicinal Chemistry)
巻:
63
号:
24
ページ:
15541-15563
発行年:
2020年
JST資料番号:
D0102A
ISSN:
0022-2623
CODEN:
JMCMAR
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)